Dexmedetomidine mitigation of renal ischaemia–reperfusion injury: comprehensive insights from cellular mechanisms to clinical application
British Journal of Anaesthesia · 2025
DOI: 10.1016/j.bja.2025.02.006 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift British Journal of Anaesthesia, 2025. Verfasst von Kevin Chotinaruemol und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anaesthesiology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand. Hauptthemen laut MEDLINE: Dexmedetomidine, Reperfusion Injury, Acute Kidney Injury, Adrenergic alpha-2 Receptor Agonists. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 80 Literaturangaben. Gefördert von: Chiang Mai University, National Research Council of Thailand.
Abstract (Originalsprache)
Renal ischaemia-reperfusion injury (IRI) is a critical cause of acute kidney injury (AKI) after major surgery, leading to elevated morbidity, mortality, and long-term renal dysfunction. Despite advances in perioperative care, the occurrence of IRI remains high. The renoprotective properties of dexmedetomidine (DEX), a selective α2-adrenergic receptor agonist, have been demonstrated, reducing oxidative stress, inflammation, apoptosis, ferroptosis, cellular senescence, and renal fibrosis while enhancing mitochondrial function and autophagy. From cellular studies to clinical applications, DEX has been effective in mitigating renal IRI, enhancing postoperative renal outcomes, and lowering the incidence of AKI in various surgical settings. This review comprehensively discusses and summarises the renoprotective effects and the underlying mechanisms of DEX, with a focus on its application across various surgical and clinical scenarios. In conclusion, DEX effectively mitigates renal IRI, as evidenced by robust in vitro, in vivo, and clinical studies. It significantly reduces kidney damage and improves surgical outcomes. However, its efficacy is less pronounced in kidney transplantation, suggesting that its renoprotective effects vary depending on the clinical context.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Anaesthesiology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
- Cardiac Electrophysiology Research and Training Centre, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand; Centre of Excellence in Cardiac Electrophysiology Research, Chiang Mai University, Chiang Mai, Th…
Förderung
- Chiang Mai University
- National Research Council of Thailand
Zitieren
APA
Chotinaruemol, K., Leurcharusmee, P., Chattipakorn, S. C., Chattipakorn, N., & Apaijai, N. (2025). Dexmedetomidine mitigation of renal ischaemia–reperfusion injury: comprehensive insights from cellular mechanisms to clinical application. British Journal of Anaesthesia. https://doi.org/10.1016/j.bja.2025.02.006
Vancouver
Chotinaruemol K, Leurcharusmee P, Chattipakorn SC, Chattipakorn N, Apaijai N. Dexmedetomidine mitigation of renal ischaemia–reperfusion injury: comprehensive insights from cellular mechanisms to clinical application. British Journal of Anaesthesia. 2025. doi:10.1016/j.bja.2025.02.006
BibTeX
@article{Chotinaruemol2025,
author = {Chotinaruemol, Kevin and Leurcharusmee, Prangmalee and Chattipakorn, Siriporn C and Chattipakorn, Nipon and Apaijai, Nattayaporn},
title = {Dexmedetomidine mitigation of renal ischaemia–reperfusion injury: comprehensive insights from cellular mechanisms to clinical application},
journal = {British Journal of Anaesthesia},
year = {2025},
doi = {10.1016/j.bja.2025.02.006}
}
EUVIMED